News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Clinical importance of eflornithine (difluoromethylornithine) for the treatment of malignant gliomas


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This drug is in clinical trials now  for recurrent anaplastic astrocytoma.   This article reviews all of the data on over 500 patients who took the drug.  Looks best for anaplastic astrocytoma, where there was a big improvement in survival! 

Disclosure: The company that makes this drug is a sponsor of the Musella Foundation


Posted on: 01/31/2018

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740